These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15905305)

  • 21. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
    Gradishar WJ
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):15-8. PubMed ID: 9364536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
    Evans TR; Yellowlees A; Foster E; Earl H; Cameron DA; Hutcheon AW; Coleman RE; Perren T; Gallagher CJ; Quigley M; Crown J; Jones AL; Highley M; Leonard RC; Mansi JL
    J Clin Oncol; 2005 May; 23(13):2988-95. PubMed ID: 15860854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
    Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
    Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
    Goldstein LJ; O'Neill A; Sparano JA; Perez EA; Shulman LN; Martino S; Davidson NE
    J Clin Oncol; 2008 Sep; 26(25):4092-9. PubMed ID: 18678836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
    Reitsamer R; Peintinger F; Prokop E; Hitzl W
    Anticancer Drugs; 2005 Sep; 16(8):867-70. PubMed ID: 16096435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer.
    Han S; Kim SB; Kang SS; Noh WC; Paik NS; Chang ES; Kim JR; Lim SH; Park HS
    Breast Cancer Res Treat; 2006 Jul; 98(1):57-61. PubMed ID: 16752226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
    Perez EA; Geeraerts L; Suman VJ; Adjei AA; Baron AT; Hatfield AK; Maihle N; Michalak JC; Kuross SA; Kugler JW; Lafky JM; Ingle JN
    Ann Oncol; 2002 Aug; 13(8):1225-35. PubMed ID: 12181246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer.
    Walker LG; Eremin JM; Aloysius MM; Vassanasiri W; Walker MB; El-Sheemy M; Cowley G; Beer J; Samphao S; Wiseman J; Jibril JA; Valerio D; Clarke DJ; Kamal M; Thorpe GW; Baria K; Eremin O
    BMC Cancer; 2011 May; 11():179. PubMed ID: 21592370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
    Learn PA; Yeh IT; McNutt M; Chisholm GB; Pollock BH; Rousseau DL; Sharkey FE; Cruz AB; Kahlenberg MS
    Cancer; 2005 Jun; 103(11):2252-60. PubMed ID: 15834928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.
    Montero AJ; Diaz-Montero CM; Deutsch YE; Hurley J; Koniaris LG; Rumboldt T; Yasir S; Jorda M; Garret-Mayer E; Avisar E; Slingerland J; Silva O; Welsh C; Schuhwerk K; Seo P; Pegram MD; Glück S
    Breast Cancer Res Treat; 2012 Feb; 132(1):215-23. PubMed ID: 22138748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
    Jones SE; Collea R; Paul D; Sedlacek S; Favret AM; Gore I; Lindquist DL; Holmes FA; Allison MAK; Brooks BD; Portillo RM; Vukelja SJ; Steinberg MS; Stokoe C; Crockett MW; Wang Y; Asmar L; Robert NJ; O'Shaughnessy J
    Lancet Oncol; 2013 Oct; 14(11):1121-1128. PubMed ID: 24007746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.
    Natoli C; Cianchetti E; Tinari N; Angelucci D; Grassadonia A; Zilli M; Ficorella C; Ricevuto E; Grossi S; De Tursi M; Carella C; Rispoli AI; Iacobelli S
    Ann Oncol; 2007 Jun; 18(6):1015-20. PubMed ID: 17369601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
    Saracchini S; Foltran L; Tuccia F; Bassini A; Sulfaro S; Micheli E; Del Conte A; Bertola M; Gion M; Lorenzon M; Tumolo S
    Breast; 2013 Dec; 22(6):1101-7. PubMed ID: 24074879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.
    Mansi JL; Yellowlees A; Lipscombe J; Earl HM; Cameron DA; Coleman RE; Perren T; Gallagher CJ; Quigley M; Crown J; Jones AL; Highley M; Leonard RC; Evans TR
    Breast Cancer Res Treat; 2010 Aug; 122(3):787-94. PubMed ID: 20559708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.
    Amat S; Mouret-Reynier MA; Penault-Llorca F; Leheurteur M; Delva R; Coudert B; Leduc B; Dauplat J; Curé H; Chollet P
    Clin Breast Cancer; 2006 Aug; 7(3):262-9. PubMed ID: 16942644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer.
    Ganem G; Tubiana-Hulin M; Fumoleau P; Combe M; Misset JL; Vannetzel JM; Bachelot T; De Ybarlucea LR; Lotz V; Bendahmane B; Dieras V
    Ann Oncol; 2003 Nov; 14(11):1623-8. PubMed ID: 14581269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study.
    Estévez LG; Sánchez-Rovira P; Dómine M; León A; Calvo I; Jaén A; Casado V; Rubio G; Díaz M; Miró C; Lobo F; Carrasco E; Casillas M; San Antonio B
    Clin Transl Oncol; 2007 May; 9(5):317-22. PubMed ID: 17525042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.